Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement
Open Access
- 1 September 2019
- journal article
- research article
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 11, 591-604
Abstract
Glaucoma is the leading cause of blindness in the developed and developing world. Not only is the clinical impact of this disease considerable, but associated economic and humanistic burdens – affecting patients, caregivers, and society – are substantial. Since glaucoma is an age-related disorder and populations in many developing countries are aging at a faster pace than in the developed world, increasing attention is being focused on ways to ameliorate the burdens of illness. In this paper, we examine the burdens of glaucoma with particular focus on developing countries, discuss some of the challenges that exist in delivering optimal glaucoma management within budget constraints, and bring into perspective how we could improve current healthcare systems, leverage technology, and strike an appropriate balance between cost and quality of care, thereby offering considerations to payors and policymakers in these countries that may result in longer-term cost savings, while concurrently striving to achieve the WHO Vision on the prevention of blindness and visual impairment.Keywords
This publication has 93 references indexed in Scilit:
- How Ocular Surface Disease Impacts the Glaucoma Treatment OutcomeBioMed Research International, 2013
- Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertensionClinical Ophthalmology, 2013
- Evidence for integrating eye health into primary health care in Africa: a health systems strengthening approachBMC Health Services Research, 2013
- Economic burden of glaucoma in Rivers State, NigeriaClinical Ophthalmology, 2012
- An Assessment of the Health and Economic Burdens of GlaucomaAmerican Journal of Ophthalmology, 2011
- Twenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol-fixed combination in primary open-angle glaucomaEye, 2011
- Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprostClinical Ophthalmology, 2011
- Short-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjectsClinical Ophthalmology, 2011
- Severity of Visual Field Loss and Health-related Quality of LifeAmerican Journal of Ophthalmology, 2007
- Glaucoma in the developing worldBMJ, 2006